INmune Bio amends 1.35M April 2024 warrants; exercise price cut to $1.95, term extended to June 2026

Inmune Bio, Inc.

Exercise price of 1,348,315 outstanding April 2024 warrants reduced to $1.95 per share.
Warrant term extended to expire on June 30, 2026 (from earlier conditional triggers).
Holders paid $0.05 per warrant ($67,416 total) as amendment consideration.
Warrants were originally issued in April 2024 offerings (April 24 & 29, 2024).
Amendment effective upon receipt of signed amendment and full consideration.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. amended Warrant Amendment with certain holders of warrants previously issued by the Company valued at $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416 (effective 2025-12-22).

Action: amendment
Counterparty: certain holders of warrants previously issued by the Company
Value: $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416
Effective: 2025-12-22

Exact text from the filing

On December 22, 2025, INmune Bio Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders of warrants previously issued by the Company in its April 2024 offerings

View on SEC.gov

287 material agreements filed in the last 30 days. Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-125282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.